News
USFDA Cautions of Heart Issues Post Novavax COVID Vaccine
Even though the company's analysis found it could reduce the likelihood of mild-to-severe disease, the US Food and Drug Administration has expressed concern about a potential hazard of heart inflammation from Novavax Inc's COVID-19 vaccine.
Within 20 days of receiving...
News
300 Drug Brands Chosen To Get QR Codes- Indian Government
The top 300 brands of drugs, including commonly used analgesics, vitamin supplements, anti-platelet medicines, pain relievers, blood-sugar-lowering medicines, and contraceptive tablets, have been shortlisted by India's drug pricing authority and will be required to add QR codes to their packages in...
News
To Be The Global Pharmacy India Must Detach From China First
India has set a massive effort to reduce its reliance on China for crucial raw materials as part of its drive to become the world's "pharmacy." India, which is already the world's third-largest producer of drugs by quantity, has one...
News
Arthritis Drugs By J&J, BMS Cut Death Risk In COVID Patients
While the COVID-19 outbreak prompted the development of novel antibody medicines and vaccinations, scientists have discovered that current medications can occasionally aid patients in their fight against the virus. A clinically meaningful trial on rheumatoid arthritis medicines in hospitalised...
News
US Biotech Affinivax To Be Bought By GSK For $3.3 billion
In a deal worth up to $3.3 billion, GlaxoSmithKline (GSK) has reached a formal agreement to buy 100% of the outstanding shares of Affinivax, a clinical-stage biopharmaceutical company based in the United States. GSK will make an initial payment...
News
Peli BioThermal Completes Innovation Webinar Series Hosted by Industry Experts
Peli BioThermal, the life science industry’s partner from discovery to distribution, recently concluded its InnovationShare webinar series. Launched in March 2021, InnovationShare was designed to fill the in-person learning gap during the height of the COVID-19 pandemic. Webinars brought...
News
Memo Therapeutics Has Begun BK Virus Therapeutic Experiment
Memo Therapeutics has brought to notice the start of a clinical trial in renal transplant patients to treat BK polyomavirus (BKV) infection.The safety, tolerability, and pharmacokinetics of MTX-005 will be assessed in a phase 1 single-blind, partially randomised, and placebo-controlled...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.